JP4563516B2 - 迅速分散性を示す投与剤形、その使用法並びにその製造方法 - Google Patents

迅速分散性を示す投与剤形、その使用法並びにその製造方法 Download PDF

Info

Publication number
JP4563516B2
JP4563516B2 JP53687898A JP53687898A JP4563516B2 JP 4563516 B2 JP4563516 B2 JP 4563516B2 JP 53687898 A JP53687898 A JP 53687898A JP 53687898 A JP53687898 A JP 53687898A JP 4563516 B2 JP4563516 B2 JP 4563516B2
Authority
JP
Japan
Prior art keywords
binder
composition according
matrix
layer
pharmacological composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53687898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512488A (ja
JP2001512488A5 (https=
Inventor
ジャデオク ヨー
サンディープ クマー
ドナルド シー モンクハウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2001512488A publication Critical patent/JP2001512488A/ja
Publication of JP2001512488A5 publication Critical patent/JP2001512488A5/ja
Application granted granted Critical
Publication of JP4563516B2 publication Critical patent/JP4563516B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP53687898A 1997-02-20 1998-02-20 迅速分散性を示す投与剤形、その使用法並びにその製造方法 Expired - Lifetime JP4563516B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3828497P 1997-02-20 1997-02-20
US3888397P 1997-02-20 1997-02-20
US60/038,883 1997-02-20
US60/038,284 1997-02-20
PCT/US1998/003256 WO1998036738A1 (en) 1997-02-20 1998-02-20 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009114753A Division JP5091910B2 (ja) 1997-02-20 2009-05-11 迅速分散性を示す投与剤形、その使用法並びにその製造方法
JP2009256374A Division JP2010120938A (ja) 1997-02-20 2009-11-09 迅速分散性を示す投与剤形医薬組成物

Publications (3)

Publication Number Publication Date
JP2001512488A JP2001512488A (ja) 2001-08-21
JP2001512488A5 JP2001512488A5 (https=) 2005-10-06
JP4563516B2 true JP4563516B2 (ja) 2010-10-13

Family

ID=26715043

Family Applications (3)

Application Number Title Priority Date Filing Date
JP53687898A Expired - Lifetime JP4563516B2 (ja) 1997-02-20 1998-02-20 迅速分散性を示す投与剤形、その使用法並びにその製造方法
JP2009114753A Expired - Lifetime JP5091910B2 (ja) 1997-02-20 2009-05-11 迅速分散性を示す投与剤形、その使用法並びにその製造方法
JP2009256374A Withdrawn JP2010120938A (ja) 1997-02-20 2009-11-09 迅速分散性を示す投与剤形医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009114753A Expired - Lifetime JP5091910B2 (ja) 1997-02-20 2009-05-11 迅速分散性を示す投与剤形、その使用法並びにその製造方法
JP2009256374A Withdrawn JP2010120938A (ja) 1997-02-20 2009-11-09 迅速分散性を示す投与剤形医薬組成物

Country Status (9)

Country Link
US (3) US6471992B1 (https=)
EP (1) EP0973507B1 (https=)
JP (3) JP4563516B2 (https=)
AT (1) ATE421318T1 (https=)
AU (1) AU736912B2 (https=)
CA (1) CA2281473C (https=)
DE (1) DE69840495D1 (https=)
ES (1) ES2318869T3 (https=)
WO (1) WO1998036738A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010120938A (ja) * 1997-02-20 2010-06-03 Massachusetts Inst Of Technology 迅速分散性を示す投与剤形医薬組成物

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934505T2 (de) * 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. Im munde zerfallende tablette enthaltend ein benzimidazole
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
AU2001273687A1 (en) * 2000-07-10 2002-01-21 Massachusetts Institute Of Technology Method and materials for controlling migration of binder liquid in a powder
US7014867B2 (en) * 2001-06-28 2006-03-21 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
EP1439824A2 (en) * 2001-10-29 2004-07-28 Therics, Inc. Three-dimensional suspension printing of dosage forms
CA2464478C (en) * 2001-10-29 2012-03-20 Therics, Inc. A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form
DE60323482D1 (de) 2002-05-06 2008-10-23 Massachusetts Inst Technology Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1804804B1 (en) 2004-09-21 2012-01-25 Hypnion, Inc. 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
EP2217229B1 (en) 2007-10-20 2020-10-14 Athenex, Inc. Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
DK2493457T3 (en) 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
AU2011233663B2 (en) * 2010-04-03 2016-04-14 Praful Doshi Medical devices including medicaments and methods of making and using same
EP2632920A1 (en) 2010-10-27 2013-09-04 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of pkm2
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
WO2012160447A1 (en) 2011-05-25 2012-11-29 Dynamix Pharmaceuticals Ltd. 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
JP6054379B2 (ja) 2011-06-07 2016-12-27 クレベクセル・ファーマＣｌｅｖｅｘｅｌ Ｐｈａｒｍａ キナーゼをモジュレートするための組成物および方法
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
US9245061B2 (en) * 2012-04-25 2016-01-26 Shapeways, Inc. Weight-based identification of three dimensional printed parts
ES3034104T3 (en) 2012-05-02 2025-08-13 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
CA2883144C (en) 2012-08-30 2023-01-17 Kinex Pharmaceuticals, Llc N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein|tyrosine kinase modulators
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
JP6466399B2 (ja) 2013-03-15 2019-02-06 アプレシア・ファーマスーティカルズ・カンパニー トピラマートの急速分散性の剤形
CA2906107C (en) * 2013-03-15 2021-08-24 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
CA2906029C (en) * 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
EP3033188A4 (en) 2013-08-16 2017-03-22 The Exone Company Three-dimensional printed metal-casting molds and methods for making the same
US20160243621A1 (en) 2013-10-17 2016-08-25 The Exone Company Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same
US20160332373A1 (en) 2013-12-23 2016-11-17 The Exone Company Methods and Systems for Three-Dimensional Printing Utilizing Multiple Binder Fluids
US11001048B2 (en) 2013-12-23 2021-05-11 The Exone Company Method of three-dimensional printing using a multi-component build powder
EP3086921B1 (en) * 2013-12-23 2019-07-31 The Exone Company Methods and systems for three-dimensional printing utilizing a jetted-particle binder fluid
EP3137113A4 (en) * 2014-04-30 2017-03-22 Blaesi, Aron H. Melt-processed polymeric cellular dosage form
EP3148730A1 (en) 2014-05-29 2017-04-05 The Exone Company Process for making nickel-based superalloy articles by three-dimensional printing
EP3169499A2 (en) 2014-07-17 2017-05-24 The Exone Company Methods and apparatuses for curing three-dimensional printed articles
WO2016081472A1 (en) 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
EP3227109B1 (en) 2014-12-03 2020-08-19 The Exone Company Process for making densified carbon articles by three dimensional printing
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
EP3108874A1 (en) * 2015-06-26 2016-12-28 TRB Chemedica AG Ophthalmologic pharmaceutical composition
US11129798B2 (en) * 2016-08-19 2021-09-28 Aron H. Blaesi Fibrous dosage form
EP3368010B1 (en) * 2015-10-26 2025-12-10 Blaesi, Aron H. Solid dosage form immediate drug release and apparatus and method for manufacture thereof
EP3429564A1 (en) * 2016-03-18 2019-01-23 Grünenthal GmbH Combination of drugs having different potency
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
EP3441065B1 (en) * 2016-04-06 2024-10-09 Astellas Pharma Inc. Fast-eluting three-dimensional molding, filament for fast-eluting three-dimensional molding, and material for fast-eluting three-dimensional molding
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
LT3458053T (lt) 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
TWI755418B (zh) 2016-08-12 2022-02-21 美商亞瑟尼克斯公司 聯芳組成物和調控激酶級聯之方法
US11040491B2 (en) 2016-10-19 2021-06-22 Shapeways, Inc. Systems and methods for identifying three-dimensional printed objects
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
US11602502B2 (en) 2017-02-24 2023-03-14 Hewlett-Packard Development Company, L.P. Three-dimensional (3D) printing a pharmaceutical tablet
EA201992116A1 (ru) 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
JP7358340B2 (ja) 2017-05-26 2023-10-10 インフィニット・マテリアル・ソリューションズ，エルエルシー 水溶性ポリマー組成物
EP4483956B1 (en) 2017-11-12 2025-12-31 Biohaven Therapeutics Ltd. TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3)
CN108066302B (zh) * 2017-12-28 2020-09-11 无限极（中国）有限公司 一种快速分散固体制剂的制备方法及制备的快速分散固体制剂
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
US10350822B1 (en) 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
DE102018107585B3 (de) * 2018-03-29 2019-03-28 Universität Rostock Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
JP7614103B2 (ja) 2018-10-15 2025-01-15 アプレシア・ファーマスーティカルズ・エルエルシー 包装内に剤形を形成する方法およびシステム
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US12103229B2 (en) * 2019-03-15 2024-10-01 Ricoh Company, Ltd. Jettable temporary binders to create removable support materials
JP7287032B2 (ja) 2019-03-20 2023-06-06 株式会社リコー シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法
AU2020277668A1 (en) * 2019-05-21 2021-11-25 Dfe Pharma Gmbh & Co. Kg Lactose powder bed three dimensional printing
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
EP3789015A1 (en) * 2019-09-05 2021-03-10 Universität Innsbruck Fast consolidating compounds
TWI734309B (zh) * 2019-12-19 2021-07-21 水星生醫股份有限公司 滲透性噴塗製作藥錠裝置
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
JP2023533478A (ja) 2020-06-26 2023-08-03 アプレシア・ファーマスーティカルズ・エルエルシー 内部空洞を有する迅速口内分散可能な錠剤
EP4238556A4 (en) 2020-10-30 2024-09-25 Triastek, Inc. GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM
EP4277624B1 (en) 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5206025A (en) 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5204055A (en) 1989-12-08 1993-04-20 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE69206443T2 (de) 1991-01-31 1996-05-30 Texas Instruments Inc Verfahren und Vorrichtung zur rechnergesteuerten Herstellung von dreidimensionalen Gegenständen aus Rechnerdaten.
EP0617613B1 (en) 1991-12-20 1996-05-29 Pfizer Inc. Porous shaped delivery devices and method of producing thereof
JP2521612B2 (ja) * 1992-05-20 1996-08-07 ウエイ・ミン・フアーマシユーテイカル・マニユフアクチヤリング・カンパニー・リミテツド 直接錠剤形成助剤
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
DE4303846A1 (de) * 1993-02-10 1994-08-11 Merck Patent Gmbh Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US6176874B1 (en) 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5503785A (en) 1994-06-02 1996-04-02 Stratasys, Inc. Process of support removal for fused deposition modeling
US5633021A (en) 1994-10-19 1997-05-27 Bpm Technology, Inc. Apparatus for making a three-dimensional article
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5560927A (en) * 1995-07-28 1996-10-01 Isp Investments Inc. Co-processing method for making a free-flowing compressible powder and tablet therefrom
US5653925A (en) * 1995-09-26 1997-08-05 Stratasys, Inc. Method for controlled porosity three-dimensional modeling
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010120938A (ja) * 1997-02-20 2010-06-03 Massachusetts Inst Of Technology 迅速分散性を示す投与剤形医薬組成物

Also Published As

Publication number Publication date
AU736912B2 (en) 2001-08-02
EP0973507B1 (en) 2009-01-21
EP0973507A1 (en) 2000-01-26
CA2281473A1 (en) 1998-08-27
CA2281473C (en) 2007-01-16
JP2001512488A (ja) 2001-08-21
JP5091910B2 (ja) 2012-12-05
US9463160B2 (en) 2016-10-11
ES2318869T3 (es) 2009-05-01
US20030133975A1 (en) 2003-07-17
ATE421318T1 (de) 2009-02-15
US9114072B2 (en) 2015-08-25
WO1998036738A1 (en) 1998-08-27
JP2009215305A (ja) 2009-09-24
US20120207929A1 (en) 2012-08-16
AU6331498A (en) 1998-09-09
US6471992B1 (en) 2002-10-29
DE69840495D1 (de) 2009-03-12
EP0973507A4 (en) 2006-08-23
JP2010120938A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
JP4563516B2 (ja) 迅速分散性を示す投与剤形、その使用法並びにその製造方法
JP2009215305A6 (ja) 迅速分散性を示す投与剤形、その使用法並びにその製造方法
Slavkova et al. Orodispersible drug formulations for children and elderly
PL211301B1 (pl) Tabletka wielowarstwowa dyspergowalna w ustach oraz sposób jej wytwarzania
Jire et al. Mouth dissolving tablet: A novel drug delivery system
BG100749A (bg) Бързо разтваряща се орална дозирана форма
KR20080026754A (ko) 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법
KR20090029255A (ko) 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의 제조방법
Chandan et al. Orally disintegrating tablets: A review
Prasad et al. A review on patent related technologies of orally disintegrating tablets
AU8731801A (en) Dosage from exhibiting rapid disperse properties, methods of use and process for the manufacture of same
PA et al. A review: On sublingual tablets
Reddy et al. Fast dissolving drug delivery system-A review
Kumar et al. Fast dissolving tablets: patient compliance dosage forms
Prajapati et al. A Contemporary Approach to The Medicate Conveyane Through Orodispersible Tablets
JP2011074015A (ja) 固形製剤及びその製造方法
Jhansi et al. A REVIEW ON ORAL DISINTEGRATING TABLETS
Shinde et al. Fast-Dissolving Orodispersible Tablets: A Review
Lavande et al. Fast dissolving drug delivery system: An overview of techniques and methods
Aqil et al. A Review of Current Formulation Trends and Technological Advancements
Alagarsamy et al. Review on Fast Dissolving Tablets Technology and Superdisintegrants
Deshmukh et al. A REVIEW ON FAST DISSOLVING TABLET.
Deepika et al. A review on orally disintegrating tablets
WO2012094302A2 (en) Drug delivery using fine fiber encapsulation
Savane et al. AN OVERVIEW ON FAST DISSOLVING TABLET

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100118

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100701

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100729

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130806

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term